217 related articles for article (PubMed ID: 12095806)
1. The effect of long-term intermittent trimethoprim/sulfamethoxazole treatment on recurrences of toxoplasmic retinochoroiditis.
Silveira C; Belfort R; Muccioli C; Holland GN; Victora CG; Horta BL; Yu F; Nussenblatt RB
Am J Ophthalmol; 2002 Jul; 134(1):41-6. PubMed ID: 12095806
[TBL] [Abstract][Full Text] [Related]
2. Trimethoprim-Sulfamethoxazole Versus Placebo in Reducing the Risk of Toxoplasmic Retinochoroiditis Recurrences: A Three-Year Follow-up.
Fernandes Felix JP; Cavalcanti Lira RP; Cosimo AB; Cardeal da Costa RL; Nascimento MA; Leite Arieta CE
Am J Ophthalmol; 2016 Oct; 170():176-182. PubMed ID: 27521607
[TBL] [Abstract][Full Text] [Related]
3. Long-term Results of Trimethoprim-Sulfamethoxazole Versus Placebo to Reduce the Risk of Recurrent Toxoplasma gondii Retinochoroiditis.
Fernandes Felix JP; Cavalcanti Lira RP; Grupenmacher AT; Assis Filho HLG; Cosimo AB; Nascimento MA; Leite Arieta CE
Am J Ophthalmol; 2020 May; 213():195-202. PubMed ID: 31926883
[TBL] [Abstract][Full Text] [Related]
4. Trimethoprim-sulfamethoxazole versus placebo to reduce the risk of recurrences of Toxoplasma gondii retinochoroiditis: randomized controlled clinical trial.
Felix JP; Lira RP; Zacchia RS; Toribio JM; Nascimento MA; Arieta CE
Am J Ophthalmol; 2014 Apr; 157(4):762-766.e1. PubMed ID: 24388839
[TBL] [Abstract][Full Text] [Related]
5. The Effect of Long-term Intermittent Trimethoprim/Sulfamethoxazole Treatment on Recurrences of Toxoplasmic Retinochoroiditis: 10 Years of Follow-up.
Silveira C; Muccioli C; Nussenblatt R; Belfort R
Ocul Immunol Inflamm; 2015 Jun; 23(3):246-7. PubMed ID: 25325434
[No Abstract] [Full Text] [Related]
6. Trimethoprim-sulfamethoxazole therapy for ocular toxoplasmosis.
Opremcak EM; Scales DK; Sharpe MR
Ophthalmology; 1992 Jun; 99(6):920-5. PubMed ID: 1630782
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal Injection of Sulfamethoxazole and Trimethoprim Associated with Dexamethasone as an Alternative Therapy for Ocular Toxoplasmosis.
Souza CE; Nascimento H; Lima A; Muccioli C; Belfort R
Ocul Immunol Inflamm; 2018; 26(7):1041-1044. PubMed ID: 28448726
[TBL] [Abstract][Full Text] [Related]
8. Prospective randomized trial of trimethoprim/sulfamethoxazole versus pyrimethamine and sulfadiazine in the treatment of ocular toxoplasmosis.
Soheilian M; Sadoughi MM; Ghajarnia M; Dehghan MH; Yazdani S; Behboudi H; Anisian A; Peyman GA
Ophthalmology; 2005 Nov; 112(11):1876-82. PubMed ID: 16171866
[TBL] [Abstract][Full Text] [Related]
9. Toxoplasmic Retinochoroiditis: Clinical Characteristics and Visual Outcome in a Prospective Study.
Aleixo AL; Curi AL; Benchimol EI; Amendoeira MR
PLoS Negl Trop Dis; 2016 May; 10(5):e0004685. PubMed ID: 27136081
[TBL] [Abstract][Full Text] [Related]
10. Toxoplasmic retinochoroiditis: The influence of age, number of retinochoroidal lesions and genetic polymorphism for IFN-γ +874 T/A as risk factors for recurrence in a survival analysis.
Aleixo ALQDC; Vasconcelos C de Oliveira R; Cavalcanti Albuquerque M; Biancardi AL; Land Curi AL; Israel Benchimol E; Reis Amendoeira MR
PLoS One; 2019; 14(2):e0211627. PubMed ID: 30753197
[TBL] [Abstract][Full Text] [Related]
11. Antibiotics for toxoplasmic retinochoroiditis: an evidence-based systematic review.
Stanford MR; See SE; Jones LV; Gilbert RE
Ophthalmology; 2003 May; 110(5):926-31; quiz 931-2. PubMed ID: 12750091
[TBL] [Abstract][Full Text] [Related]
12. The role of intravitreal trimethoprim/sulfamethoxazole in the treatment of toxoplasma retinochoroiditis.
Choudhury H; Jindal A; Pathengay A; Bawdekar A; Albini T; Flynn HW
Ophthalmic Surg Lasers Imaging Retina; 2015 Jan; 46(1):137-40. PubMed ID: 25559528
[TBL] [Abstract][Full Text] [Related]
13. Comment on: Long-term Results of Trimethoprim Sulfamethoxazole Versus Placebo to Reduce the Risk of Recurrent Toxoplasma gondii Retinochoroiditis.
Kumawat D; Samanta R; Sahay P
Am J Ophthalmol; 2020 Dec; 220():216-217. PubMed ID: 33097176
[No Abstract] [Full Text] [Related]
14. Reply to Comment on: Long-term Results of Trimethoprim Sulfamethoxazole Versus Placebo to Reduce the Risk of Recurrent Toxoplasma gondii Retinochoroiditis.
Fernandes Felix JP; Cavalcanti Lira RP; Grupenmacher AT; de Assis Filho HLG; Cosimo AB; Nascimento MA; Leite Arieta CE
Am J Ophthalmol; 2020 Dec; 220():217-218. PubMed ID: 33097174
[No Abstract] [Full Text] [Related]
15. [Toxoplasmic retinochoroiditis].
Zhang MH; Yang HZ
Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 1992; 10(3):215-8. PubMed ID: 1307280
[TBL] [Abstract][Full Text] [Related]
16. Recurrent toxoplasmic retinochoroiditis. Significance of perilesional satellite dark dots seen by indocyanine green angiography.
Bernasconi O; Auer C; Herbort CP
Ocul Immunol Inflamm; 1997 Sep; 5(3):207-11. PubMed ID: 9326766
[TBL] [Abstract][Full Text] [Related]
17. Toxoplasmic maculopathy with bacillary layer detachment in a pediatric patient.
Sanchez-Quiros J; Burgos-Blasco B; Montolío-Marzo E; Medina-García E; Ramos-Amador JT; Diaz-Valle D
J AAPOS; 2023 Jun; 27(3):176-179. PubMed ID: 37054965
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal clindamycin plus dexamethasone versus classic oral therapy in toxoplasmic retinochoroiditis: a prospective randomized clinical trial.
Baharivand N; Mahdavifard A; Fouladi RF
Int Ophthalmol; 2013 Feb; 33(1):39-46. PubMed ID: 23053769
[TBL] [Abstract][Full Text] [Related]
19. [Interest in treatment with subconjunctival clindamycin in toxoplasmic retinochoroiditis].
Ben Zina Z; Abid D; Kharrat W; Chaker N; Aloulou K; Chaâbouni M
Tunis Med; 2001 Mar; 79(3):157-60. PubMed ID: 11471444
[TBL] [Abstract][Full Text] [Related]
20. Does atovaquone prolong the disease-free interval of toxoplasmic retinochoroiditis?
Winterhalter S; Severing K; Stammen J; Maier AK; Godehardt E; Joussen AM
Graefes Arch Clin Exp Ophthalmol; 2010 Aug; 248(8):1187-92. PubMed ID: 20437247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
